Skinvisible ( (SKVI) ) has provided an announcement.
Skinvisible Pharmaceuticals has announced the development of a cutting-edge transdermal obesity treatment utilizing its proprietary Invisicare technology, which delivers medication through the skin without the need for patches or injections. Highlighted in Drug Development & Delivery, the company’s obesity formulation achieved a 99.6% penetration over six hours in studies, showcasing the potential for a non-invasive, sustained drug delivery method. With obesity on the rise and a market that could reach up to $144 billion by 2030, Skinvisible is actively pursuing partnerships to bring these transdermal therapies to market, offering a more comfortable and convenient treatment alternative for patients.
For a thorough assessment of SKVI stock, go to TipRanks’ Stock Analysis page.
